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PPARs, most notably PPAR-γ, play a crucial role in regulating the activation of alveolar macrophages, which in turn occupy a
pivotal place in the immune response to pathogens and particulates drawn in with inspired air. In this review, we describe the dual
role of the alveolar macrophage as both a ﬁrst-line defender through its phagocytotic activity and a regulator of the immune re-
sponse. Depending on its state of activation, the alveolar macrophage may either enhance or suppress diﬀerent aspects of immune
function in the lung. We then review the role of PPAR-γ and its ligands in deactivating alveolar macrophages—thus limiting the
inﬂammatory response that, if unchecked, could threaten the essential respiratory function of the alveolus—while upregulating
the cell’s phagocytotic activity. Finally, we examine the role that inadequate or inappropriate PPAR-γ responses play in speciﬁc
lung diseases.
Copyright © 2007 Monica R. Smith et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Peroxisome proliferator-activated receptors (PPARs) are
members of the nuclear-receptor superfamily. Their name
derives from the ﬁrst-discovered member of the class, PPAR-
α, whose activation induces proliferation of peroxisomes in
the liver; no similar eﬀect is seen with other members of
the class, however. These receptors act as transcription fac-
tors, forming heterodimers with the retinoid X receptor and
then binding to speciﬁc response elements (PPREs) in the
promoter regions of the genes they regulate. When activated
by appropriate ligands, PPARs undergo a conformational
change that leads to release of corepressors and binding of
coactivator molecules, with consequent increases in tran-
scription of the genes involved. Some evidence suggests that
in the absence of activating ligands, PPARs may bind core-
pressors and downregulate expression of genes with PPRE-
containing promoters [1].
There are three PPAR isoforms: PPAR-α,P P A R - γ,a n d
PPAR-β/δ. Each of the isoforms is the product of a diﬀer-
ent gene. PPAR-β/δ is expressed in almost every tissue of the
body. PPAR-α is most commonly thought of in connection
with hepatocytes and PPAR-γ with adipocytes, but in fact
both are expressed in a variety of cells and tissues. Broadly
speaking, PPAR-α regulates lipid metabolism, lipoprotein
formation and transport as well as lipid catabolism, whereas
PPAR-β/δ promotes lipid oxidation, and PPAR-γ promotes
adipogenesis [2]. Each has other functions in speciﬁc tis-
sues, however. For example, PPAR-α inhibits proliferation
of vascular smooth muscle cells in response to injury [3]
and antagonizes the eﬀects of angiotensin II on the vas-
cular wall [4]. In skin, PPAR-β/δ induces terminal diﬀer-
entiation of keratinocytes [5]. Activation of PPAR-γ in en-
dothelial and vascular smooth muscle cells likewise inhibits
expression of the angiotensin II receptor [6]a n dl o w e r s
blood pressure in hypertensive mice [7]. PPAR-γ agonists
have also been shown to exert antiproliferative eﬀects on
a variety of cancer cells [8]. This has led to widespread
discussion of their possible usefulness in cancer therapy
(e.g., for breast cancer [9]) and even to a few early clinical
trials.
All three PPARs have signiﬁcant anti-inﬂammatory
roles in cells of the immune system. PPAR-γ has been
found in monocytes/macrophages [10, 11], neutrophils [12],
dendritic cells [13] ,B[ 14]a n dT[ 15–17]l y m p h o c y t e s ,
eosinophils [18], natural killer cells [19], and mast cells
[20]. PPAR-γ downregulates expression of a number of
proinﬂammatory mediators while upregulating expression
of anti-inﬂammatory mediators (reviewed in [21]). PPAR-
α is found in essentially all the same cells as PPAR-γ with2 PPAR Research
the notable exception of (mature) dendritic cells and alveo-
lar macrophages [22]. Among the many anti-inﬂammatory
eﬀects of PPAR-α that have been demonstrated is inhibition
of airway inﬂammation induced by lipopolysaccharide [23]
andoftheinﬂammatoryear-swellingresponsetoleukotriene
B4 [24]. Furthermore, the acute anti-inﬂammatory eﬀects of
the anticholesterolemic drug simvastatin have been shown to
bemediatedbyPPAR-α[25].TheroleofPPAR-β/δ intheim-
mune system has been less extensively investigated and while
alveolar macrophages have been found to express PPAR-β/δ
[22], no studies to our knowledge have demonstrated the
functional importance of this receptor in these cells. PPAR-
β/δ has been shown, however, to decrease the expression of
proinﬂammatory mediators by other types of macrophages
[26].
Monocytes are produced in the bone marrow but, un-
der the inﬂuence of chemoattractant molecules, migrate to
various tissues of the body where they diﬀerentiate into
macrophages and other cells of the immune system. The
amount of PPAR-γ in monocytes is relatively low [27]b u t
increases sharply during diﬀerentiation [28]. Furthermore,
PPAR-γ agonists stimulate monocyte-macrophage diﬀeren-
tiation [27, 29]. The resulting macrophages play key roles
in regulation of the immune process. Macrophages are best
recognized as phagocytes, but their secretion of either anti-
inﬂammatory or proinﬂammatory mediators, depending on
their own state of activation, plays a crucial role in reg-
ulation of immune system activity. Phenotypic character-
istics of macrophages diﬀer depending upon the tissue in
which they diﬀerentiate and remain. This is particularly true
with macrophages of the alveolus which diﬀer substantially
from peritoneal macrophages or macrophages diﬀerentiated
in vitro from blood-borne monocytes.
In this review, we examine the role of PPARs, focusing
predominantly on the PPAR-γ subtype, in regulating the ac-
tivities of alveolar macrophages, which occupy a pivotal spot
both as primary phagocyte and as primary regulator of the
immunesystem’sresponsetopathogensandparticulatesthat
reachthealveolusthroughinspiredair.Wealsoexamineways
in which inadequate or inappropriate PPAR-γ responses can
contribute to diseases of the lung.
2. THE ALVEOLAR MACROPHAGE: PIVOTAL
REGULATOR OF IMMUNE RESPONSE
The lung is constantly exposed to noxious agents, both liv-
ing pathogens and nonliving particulates, that are drawn
into the alveolus with inspired air. The alveolar macrophage
represents the ﬁrst line of defense against these agents. Yet
the gas-exchange function of the alveolus depends crucially
on the thinness and integrity of the structures separating
the air space from the pulmonary capillary. An inﬂamma-
tory response, with edema and perhaps subsequent ﬁbrosis,
wouldseverelyimpactthisessentialfunction.Thus,whilein-
ﬂammation may at times be necessary to eradicate invading
pathogens, this response must be strictly regulated, as an in-
ﬂammatory response to every arriving particle or organism
would substantially diminish the lung’s functional capacity.
2.1. Alveolarmacrophages:originandfunction
T h e r ea r et w om a j o rt y p e so fr e s i d e n ti m m u n ec e l l si n
the alveolus: dendritic cells and macrophages. Neutrophils,
eosinophils, lymphocytes, and natural killer cells are also
present but tend to be less prominent in the absence of overt
inﬂammation. The dendritic cell, which forms part of the
alveolar lining, mediates adaptive immunity. Indeed, it is the
dendritic cell that presents antigens to other eﬀector cells of
the adaptive immune system and thus induces an antigen-
speciﬁc response. The macrophage is the primary mediator
of the innate immune response that does not require recog-
nition of a speciﬁc antigen.
Most alveolar macrophages are derived from circulating
monocytes. These monocytes are recruited into the lung,
where they diﬀerentiate into macrophages under inﬂuence
of the lung environment. In patients who have received bone
marrow transplants, macrophages with the donor genotype
replacethosewithhostgenotype;kineticsindicateanaverage
macrophage lifespan of 81 days [30]. There is also evidence,
however, for proliferation of diﬀerentiated macrophages
withinthealveolus,sincereplicatingmacrophagescanbeob-
served in bronchoalveolar lavage ﬂuid and are more com-
mon in smokers and others with chronic lung inﬂammation
[31]. Observations during acute lung inﬂammation induced
by heat-killed Bacillus Calmette-Gu´ erin indicate that even
though local proliferation increased approximately 3-fold,
the inﬂux of monocytes was eight times as great [32]. In the
normalsteadystate,greaterthan70%ofthemacrophagesare
derived from circulating monocytes [33]. Substances known
toinducethemonocyte-macrophagetransitioninclude1,25-
dihydroxycholecalciferol and IL-10, as well as serum factors
that remain less well deﬁned [34–37].
The most obvious role of the alveolar macrophage is as
a phagocyte. Phagocytes engulf viruses, bacteria, fungal cells,
and a variety of appropriately sized nonliving particulates.
Once engulfed, these particulates may be degraded if they
are susceptible to the enzymes of the lysosomal system, as
many (but not all) bacteria and fungi are. Otherwise, the
particles will remain encapsulated within the macrophages
until the latter either die (probably being engulfed by other
macrophages), are transferred to lymph nodes draining the
site, or are cleared from the airway by the mucociliary system
[38].
Phagocytosis of many pathogens is mediated by the
macrophage’s Toll-like receptors (named for their sequence
similarity to the Toll protein that governs dorsal-ventral pat-
terning in Drosophila larvae). As recently reviewed by Akira
[39], there are multiple Toll-like receptors; each recognizes
ad i ﬀerent microbial component or pathogen-associated
molecular pattern (PAMP) which initiates signaling path-
ways through selective utilization of intracellular adaptor
molecules. Phagocytosis may also be triggered by receptors
for complement and the Fc portion of antibodies, thus tar-
geting pathogens that have been recognized by the adap-
tive immune system [40]. There are also scavenger recep-
tors that facilitate phagocytosis of particles coated with
surfactant proteins A and D, which bind to a wide va-
riety of bacteria and opsonize them (i.e., “tag” them forMonica R. Smith et al. 3
phagocytosis) [41–43]. Finally, there are scavenger recep-
tors that target inhaled particulates that have not otherwise
been “tagged” by the immune system or surfactant proteins
[44].
Alveolar macrophages are also involved in maintenance
and remodeling of lung tissue, on the one hand secreting
growth factors and cytokines that stimulate ﬁbroblast pro-
liferation and matrix synthesis and on the other hand pro-
ducing matrix-degrading proteinases. Macrophage-secreted
factors supporting matrix production include transforming
growthfactor-β (TGF-β)[45]andinsulin-likegrowthfactor-
1[ 46]. In addition to stimulating ﬁbroblast proliferation,
these cytokines stimulate production of collagen and of tis-
sue inhibitors of matrix metalloproteinases (MMPs) while
inhibiting metalloproteinase synthesis. A major matrix-
degrading enzyme produced by alveolar macrophages is
MMP-1[47],althoughotherMMPsaswellasserineandcys-
teine proteinases also originate in macrophages.
A crucial nonimmune activity of macrophages is main-
tenance of pulmonary surfactant homeostasis. Surfactant,
which serves to prevent alveolar collapse by reducing surface
tension, is a mixture of proteins and lipids (mostly phospho-
lipids) secreted by the epithelial cells of the lung [48]. Newly
produced and biologically active surfactant takes the form of
relatively large protein-lipid aggregates. Over time, however,
the mechanical stresses associated with alveolar motion re-
duce the aggregates’ size until they no longer provide eﬀec-
tive surface tension reduction. These small, nonactive aggre-
gates are taken up by both the epithelial cell and the alveolar
macrophage [49]; most of those taken up by the epithelial
cell are recycled, while those taken up by the macrophage are
degraded and eliminated [50]. Hence, the macrophage plays
a major role in elimination of excess surfactant.
2.2. Keyroleofalveolarmacrophagesinlung
immunesystemregulation
Factors expressed by the innate immune system, including
antibacterialproteinsfoundinthepulmonarysurfactant,are
relatively noninjurious to the pulmonary epithelium. Only
the generation of bactericidal reactive oxygen species is likely
to have toxic eﬀects. The adaptive immune system, on the
other hand, relies heavily on inﬂammatory reactions to ﬁght
invading pathogens. Thus, in the lung it is desirable to rely
on the innate immune system whenever possible.
When macrophages are stimulated by lipopolysaccharide
andothermicrobialcomponents,thesecellsrespondbyelab-
orating substances that upregulate the innate immune sys-
tem, including chemoattractant molecules that recruit neu-
trophils and monocytes. Major chemoattractants produced
by alveolar macrophages include leukotriene B4 [51]a n d
chemokines, particularly CXCL8 (IL-8) and CCL3 [52–54].
Conversely, in most circumstances the alveolar macro-
phage suppresses adaptive immunity, both through direct
actions on the T cell and by inhibiting antigen presenta-
tion by dendritic cells. Depletion of alveolar macrophages
in mice and rats, followed by antigen challenge, results in a
marked increase in production of all antibody classes and in
the number of T cells found in the lung and regional lymph
nodes [55]. Antigen presenting activity of the dendritic cells
is also increased [56]. Macrophages suppress lymphocyte ac-
tivation via the production of nitric oxide, prostaglandin E2,
and immunosuppressive cytokines including TGF-β and IL-
10 [57, 58]. More recently it has been found that these im-
munosuppressive cytokines are the product of an “alterna-
tively activated,” or “M2,” macrophage induced by the TH2
cytokines IL-4 and IL-13 [59, 60].
There will be times when the innate system is over-
whelmedandtheadaptivesystemmustbeactivated.Arecent
elegant paper by Takabayshi et al. explains how the alveolar
m a c r o p h a g eb e c o m e sa c t i v a t e da n di nt u r na b l et os t i m u l a t e
the adaptive immune system and how this activation is re-
versed in time in the absence of continued stimulation [61].
3. PPARs AND THE ALVEOLAR MACROPHAGE
Macrophages diﬀerentiated from monocytes in vitro express
all three isoforms of PPAR: PPAR-α [28], PPAR-β/δ [62],
and PPAR-γ [28]. Activation of PPAR-α,b u tn o to fP P A R - γ,
increased expression of NADPH oxidase and thereby facili-
tated production of reactive oxygen species [63]. Expression
of some, butnot all,proinﬂammatory moleculesisdecreased
in macrophages isolated from PPAR-β/δ knockout mice and
increased in macrophages overexpressing the receptor. How-
ever, expression of these molecules was decreased by PPAR-
β/δ agonists, suggesting that it is speciﬁcally the unliganded
receptor that is proinﬂammatory and that ligands may in-
duce a switch between pro- and anti-inﬂammatory states
[64]. In addition, both PPAR-β/δ and PPAR-γ agonists limit
the ability of lipopolysaccharide to induce molecules such as
nitric oxide synthase that are associated with inﬂammation
[65].
In liver, liver-type fatty acid binding protein (L-FABP) is
required for transport of both PPAR-α and PPAR-γ ligands
into the nucleus [66]. Interestingly, alveolar macrophages are
the only cells of the myeloid lineage to contain L-FABP [22].
Since the promoter region of the L-FABP gene contains a
bindingsiteforPPARs[66],thisrepresentsapotentialsignal-
enhancing feed-forward mechanism.
PPAR-γ is known to be highly expressed in alveo-
lar macrophages [11, 67, 68]. This is in contrast to peri-
toneal macrophages, where the amount is quite low in
the macrophages normally resident in the peritoneum
but sharply higher in activated macrophages elicited by
thioglycolate [11]. The expression of PPAR-γ in alveolar
macrophages is further upregulated by IL-4 [68]. Con-
versely, PPAR-γ is downregulated in activated peritoneal
macrophages by interferon-γ and lipopolysaccharide [65].
Interestingly,wefoundthatthepredominantisoforminalve-
o l a rm a c r o p h a g e si sP P A R - γ2, previously considered speciﬁc
for adipocytes [68].
Although the amount of PPAR-γ in monocytes is
markedly lower than in macrophages, its activation in a
monocyte-like leukemia cell line has been shown to pro-
mote diﬀerentiation into cells displaying macrophage mark-
ers [27]. However, experiments with stem cells genetically
lacking PPAR-γ have shown that this receptor is not essen-
tial for development of macrophages [69, 70].4 PPAR Research
Asinmanyothertissues,exactlywhichofthemanynatu-
ral ligands are physiologically most important is not entirely
clear. One of the highest-aﬃnity natural ligands currently
known is 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2), but
levels of this molecule may be quite low in many tissues and
often do not correlate with responses presumed to be medi-
ated by PPAR-γ [71]. On the other hand, this ligand is plen-
tifulinhistiocytes anddendritic cellsfromavarietyoftissues
[72]. An argument for the importance of 15d-PGJ2 in alveo-
larmacrophagesisthatlipopolysaccharide-inducedsynthesis
ofsecretorytypeIIAphospholipaseA2 isinhibitedbyarachi-
donicacid,aprecursorof15d-PGJ2 butnotbyitsnonmetab-
olizable analog 5,8,11,15-tetraynoic acid [73]. Arachidonic
acidis convertedto15d-PGJ2 byapathwaydependentonthe
cyclooxygenase-2 (COX-2) enzyme, and COX-2 inhibitors
blocked the eﬀect of arachidonic acid. Furthermore, the ef-
fect of arachidonic acid was mimicked by administration of
either 15d-PGJ2 or the PPAR-γ ligand ciglitazone. Thus, the
same eﬀect is produced by synthetic PPAR-γ ligands and a
metabolic precursor of 15d-PGJ2, suggesting that the eﬀects
observed result from binding of 15d-PGJ2 or a closely related
compound.
It has also been shown [74] that mice lacking lysosomal
acid lipase, and thus deﬁcient in free fatty acids (including
arachidonic acid), have an inﬂammatory phenotype in the
lung that is largely eliminated by PPAR-γ agonists. In this
case, however, the alteration is too far upstream to clearly
identify the speciﬁc PPAR-γ ligand involved. Additionally,
evidence that a given ligand plays a crucial role in one sit-
uation does not rule out involvement of diﬀerent ligands in
other situations.
In addition to 15d-PGJ2, known ligands for PPAR-
γ include 13-hydroxyoctadecadienoic acid (13-HODE)
and 15-hydroxyeicosatetraenoic acid (15-HETE), respec-
tively produced from linoleic and arachidonic acids by
12/15-lipoxygenase. In peritoneal macrophages, the anti-
inﬂammatory cytokine IL-4 upregulates expression of both
12/15-lipoxygenase and PPAR-γ, suggesting an important
roleforthoseunsaturatedfattyacidderivativesinatleastthat
speciﬁc type of macrophage [75]. 13-HODE is also found as-
sociated with oxidized LDL and is believed to play a role in
regulating fatty streak macrophages [29].
Recent studies have revealed relatively large amounts of
nitrated fatty acids in human blood and urine, with deriva-
tives of oleic acid being particularly abundant [76]. These
substances, which are presumably generated as a result of
nitric oxide production during inﬂammation, have been
shown to act as potent PPAR-γ ligands at physiological con-
centrations [76] and to inhibit lipopolysaccharide-induced
secretion of proinﬂammatory cytokines by macrophages
[77]. However, this latter eﬀect was reported to reﬂect di-
rectalkylationofNF-κBratherthanPPAR-γ activation.Allof
these natural ligands are fatty acid derivatives. The alveolus,
including its resident macrophages, is constantly bathed in
lipid-rich surfactant. Most of these lipids are phospholipids,
but about 10% are neutral lipids including free fatty acids
[78]. The essential role of free fatty acids in the production
of PPAR-γ ligands has been demonstrated by Lian et al. [74]
and by Yan et al. [79]. The former group showed that inﬂam-
mation and abnormal gene expression in the lungs of lyso-
somal acid lipase knockout mice could be largely reversed by
9-hydroxyoctadenanoic acid or ciglitazone, while the latter
group demonstrated that expression of lysosomal acid lipase
speciﬁcally in macrophages had the same eﬀect in a variety
of tissues throughout the body. These results are compati-
ble with the importance of free fatty acid release speciﬁcally
within the macrophage, but it has also been shown that ad-
dition of exogenous arachidonic acid to macrophages cul-
tured ex vivo had eﬀects that appeared to be mediated by
PPAR-γ [73]. Thus, PPAR-γ expressing cells in the alveolus
are constantly bathed in precursors for the receptor’s ligands.
Thealveolarmicroenvironmentisimmunosuppressiveinthe
absence of speciﬁc stimulation—a conclusion supported by
the ﬁnding that PPAR-γ binds to PPREs in resting alveolar
macrophages from healthy controls but the binding is greatly
reduced in those from patients with a chronic inﬂammatory
condition such as pulmonary sarcoidosis [80].
3.1. EffectsofPPAR-γ agonistsonthe
alveolarmacrophage
Early investigations of the role of PPAR-γ in activated
peritoneal macrophages demonstrated that 15d-PGJ2 and
rosiglitazone inhibited expression of inducible nitric oxide
synthase, gelatinase B, and scavenger receptor A [11]. Sim-
ilarly, in alveolar macrophages, 15d-PGJ2 and troglitazone
inhibited the ability of lipopolysaccharide to induce synthe-
sis of tumor necrosis factor-α while simultaneously upreg-
ulating expression of CD36, a scavenger receptor that me-
diates phagocytosis of (among other things) apoptotic neu-
trophils [67]; phagocytosis of apoptotic neutrophils is typi-
cal during the resolution of inﬂammation. In another exper-
iment, treatment with PPAR-γ agonists inhibited the oxida-
tiveburstfollowingadditionof4β-phorbol-12-myristate-13-
acetate (PMA), expression of inducible nitric oxide synthase
following treatment with lipopolysaccharide plus interferon-
γ, and production of IL-12 following lipopolysaccharide
treatment [68].
Given the role that phagocytosis of apoptotic cells plays
in resolution of inﬂammation, it is interesting that the pres-
ence of apoptotic cells inhibits the PMA-induced oxida-
tive burst through a mechanism that requires PPAR-γ [81].
Thus, PPAR-γ inhibits potentially destructive eﬀects associ-
atedwithinﬂammation,suchasthereleaseofreactiveoxygen
species, while facilitating the resolution of inﬂammation. On
theotherhand,however,recentworkhasshownthatPPAR-γ
supportsnoninﬂammatoryprotectiveeﬀectsbyupregulating
activityofalveolarmacrophageFcγ surfacereceptor(unpub-
lished results) which is of particular relevance as the Fcγ re-
ceptor mediates phagocytosis of bacteria and other particles
opsonized by attachment of antibodies belonging to the im-
munoglobulin G class.
Takabayashi et al. demonstrated that actin polymeriza-
tion is a crucial step in the change of shape that lifts the
alveolar macrophage oﬀ the epithelial cell and leads to ac-
tivation [61]. Although the possible involvement of PPAR-γ
in this process has not been directly investigated in alveolarMonica R. Smith et al. 5
macrophages, PPAR-γ agonists have been shown to inhibit
actin polymerization in vascular monocytes [82].
3.2. PPAR-γ effectsinotherimmunecellsofthelung
Macrophages are not the only essential immune cells of the
lung. The dendritic cell, which is also derived from mono-
cytes and resides within the alveolar wall, takes up and pro-
cesses foreign substances into antigenic fragments. These
cells then migrate to the draining lymph nodes, where they
present these antigens to helper T cells that promote adap-
tive immune responses.
Emerging data convincingly demonstrate that PPAR-γ
agonists inﬂuence dendritic cell function. For example, ex-
posure of dendritic cells to PPAR-γ ligands during diﬀerenti-
ation in vitro results in a reduction in the ability of these cells
to generate an immune response [13]. These eﬀects include a
reduction in secretion of proinﬂammatory cytokines and in
expression of molecules essential for migration to regional
draining lymph nodes where antigen presentation occurs.
Dendritic cell responses to stimulation of Toll-like receptors
that constitutively respond to speciﬁc molecular stimuli are
likewise reduced [83]. In fact, ligands for all three PPAR iso-
forms reduce expression of costimulatory molecules and the
ability of dendritic cells to stimulate T cells in a mixed lym-
phocyte reaction [84]. Furthermore, treatment of dendritic
cellswithPPAR-γ ligandsduringantigen-stimulatedmatura-
tion (a step following diﬀerentiation) has been shown to re-
duce the eosinophilic response in a murine model of asthma
following reinjection of the in vitro-treated cells [85]. In vivo
treatment with PPAR-γ ligands has also been shown to in-
hibit migration of epidermal dendritic cells to the draining
lymph nodes [86]. In one study, exposure during and after
diﬀerentiationinvitroproduceddendriticcellswithagreatly
blunted ability to release proinﬂammatory chemokines and,
even more signiﬁcantly, to activate T-lymphocytes through
antigen presentation [13]. This blunted response was shown
to be alleviated by administration of IL-12.
Neutrophils also play an important role in lung inﬂam-
matoryresponses.Althoughtherehavebeennumerousstud-
ies demonstrating a reduction in neutrophil-predominant
inﬂammation following administration of PPAR-γ agonists
[12], studies assessing direct eﬀects on human neutrophils
arelimited.Mostnotably,weshowedthatPPAR-γ expression
in neutrophils was upregulated by tumor necrosis factor-α or
IL-4 and that incubation of resting human neutrophils with
PPAR-γ agonists reduced chemotactic responses to IL-8 or
formylmethionylleucylphenylalanine (FMLP) (unpublished
results). Additionally, Imamoto et al. showed that the in-
creased expression of neutrophil CD11b/CD18 surface inte-
grins induced by FMLP was suppressed by pioglitazone [87].
3.3. MechanismsofPPAR-γ actioninalveolar
macrophages
The molecular mechanisms through which PPAR-γ actshave
been well characterized. What is often not explicitly appreci-
ated is that the coactivators used by PPAR-γ are also used
by other nuclear transcription factors, including cAMP re-
sponse element-binding protein (CREB) [88, 89], activator
protein-1 (AP-1) [88], basic helix-loop-helix factors [90],
signal transducers and activators of transcription (STATs)
[91–93], and nuclear factor-κB( N F - κB) [94]. Because the
number of coactivator molecules is limited, PPAR-γ activa-
tion may restrict availability of coactivators to other nuclear
transcriptionfactorsandtherebydownregulateexpressionof
genes under their control. There is also evidence that PPAR-
γ may directly bind to these and other transcription factors,
thus preventing them from binding to DNA and promot-
ing gene transcription [87, 95–98]. Indeed, the initial report
of PPAR-γ activation in peritoneal macrophages focused on
downregulation of genes controlled by AP-1, STAT-1, and
NF-κB[ 11]. PPAR-γ interference with activity of NF-κB also
appears likely in alveolar macrophages, since PPAR-γ ago-
nists inhibit the ability of lipopolysaccharide to induce syn-
thesis of secretory type IIA phospholipase A2,w h i c hi sp r o -
moted by NF-κB[ 73].
Additionally, PPAR-γ interacts with liver X receptor-α
(LXR-α). In contrast to the interactions with NF-κB, how-
ever, those with LXR-α are synergistic [99]. Both PPAR-γ ag-
onists and LXR-α agonists inhibit the ability of lipopolysac-
charide to induce an inﬂammatory phenotype in cultured
macrophages. However, when suboptimal concentrations of
each agonist type are added simultaneously, the eﬀects are
far greater than would be seen with either agonist alone. In
this study, these eﬀects were associated with reduced activity
of NF-κB. Interestingly, LXR-α agonists increase expression
and DNA binding of PPAR-γ [69, 99, 100], while PPAR-γ ag-
onists increase LXR-α expression in mesangial cells [101].
4. PPAR-γ IN LUNG DISEASE
There are several lung diseases in which alveolar
macrophages appear to play a crucial role in disease
pathogenesis and where PPAR-γ agonists may prove useful
as therapy. In other cases the role of the alveolar macrophage
may be less clear but studies indicate that PPAR-γ ligands
m a ya l s op r o v et ob eb e n e ﬁ c i a l .
4.1. Pulmonarysarcoidosis
Sarcoidosisisastateofchronicgranulomatousinﬂammation
that may aﬀect multiple organs, especially the lungs [102].
The cause of sarcoidosis remains unknown, but the pathol-
ogy is characterized by greatly enhanced activation of the in-
nate and adaptive immune systems [103, 104]. This is ac-
companiedbyincreasedexpressionofcytokinessuchasIL-2,
IL-12, IL-18, and interferon-γ, with the alveolar macrophage
having been demonstrated as a source for at least some of
these molecules. Given the established role of PPAR-γ in
maintaining alveolar macrophages in a quiescent state and
the macrophage’s role in activating other components of the
immune system, examination of macrophage PPAR-γ levels
appeared warranted. Indeed, alveolar macrophages from pa-
tients with sarcoidosis had much lower levels of PPAR-γ and
higher levels of NF-κB activity than those from healthy con-
trols[80].Whileacausalrelationshipbetweenthisdeﬁciency
of PPAR-γ and the heightened state of inﬂammation that6 PPAR Research
characterizes sarcoidosis is plausible, the eﬀects of PPAR-
γ agonist administration or factors known to upregulate
PPAR-γ expression on disease course remain to be investi-
gated.
4.2. Alveolarproteinosis
Alveolar proteinosis is a condition in which excessive
amounts of pulmonary surfactant, both phospholipids and
proteins, accumulate in the lung airspaces [105]. Phospho-
lipid inclusions are also prominent in alveolar macrophages
[106]. Most human alveolar proteinosis (not obviously sec-
ondarytootherconditions)isassociatedwithautoantibodies
to granulocyte-macrophage colony stimulating factor (GM-
CSF) [107, 108]; animal models in which either GM-CSF or
its receptor is genetically deleted can mimic the disease. The
current treatment is removal of excess surfactant through
whole-lung lavage under general anesthesia, but preliminary
studies support the potential eﬃcacy of subcutaneous GM-
CSF treatment in the human disease [109, 110].
GM-CSF, which is produced by a number of cell types in
the lung [111], promotes growth, diﬀerentiation, and acti-
vation of cells of the phagocytic lineage [112, 113] and has
been shown to promote accumulation and proliferation of
alveolar macrophages [114–116]. However, because its activ-
ities overlap those of other cytokines [117], hematopoiesis
and myelopoiesis are essentially normal in GM-CSF knock-
out mice [118–121].
Since GM-CSF has been shown to upregulate PPAR-
γ in cell culture [11, 75], Bonﬁeld and colleagues exam-
ined PPAR-γ expression in alveolar macrophages from pa-
tients with alveolar proteinosis [122]. Not only was PPAR-γ
mRNA and protein expression much lower than in alveolar
macrophages from healthy controls, but macrophage expres-
sion of the PPAR-γ-dependent scavenger receptor CD36 was
also lower. Furthermore, treatment with GM-CSF fully re-
stored PPAR-γ to normal levels. The conclusion that GM-
CSF acts at least partially through eﬀects on macrophage
PPAR-γ is supported by recent observations that GM-CSF
also upregulates PPAR-γ in macrophages of the fatty streak
[123].
These observations raise interesting but speculative and
largely unexplored therapeutic possibilities. It could be
worth considering the possibility that PPAR-γ agonists, in-
cludingthethiazolidinediones,mightproveaseﬀectiveasthe
subcutaneous GM-CSF currently being investigated as a pos-
sible treatment.
4.3. Lunginjury
Injury to the lung, by inhaled irritant for example, is char-
acterized by exuberant inﬂammation, epithelial injury, and
often the development of secondary pulmonary ﬁbrosis. An
appealing animal model of acute lung injury involves the
intratracheal administration of ﬂuorescein isothiocyanate.
This insult results in a neutrophil-predominant inﬂamma-
tion accompanied by leakage of protein into the alveolus
that is maximal at 3 to 7 days, while patchy ﬁbrosis devel-
o p s3t o4w e e k sa f t e re x p o s u r et ot h ea g e n t[ 124]. Using this
model, we found that PPAR-γ expression increases in alve-
olar macrophages and that pretreatment with pioglitazone
for 5 days prior to ﬂuorescein isothiocyanate exposure sig-
niﬁcantly reduced inﬂammation and reduced the number of
neutrophils in bronchoalveolar lavage ﬂuid by 50%, but did
notaﬀectexpressionofproinﬂammatorycytokines[12].The
lack of eﬀect on cytokine expression led us to postulate that
pioglitazone was acting directly on the neutrophil to impair
the ability of these cells to migrate in response to secreted
chemoattractants.
In humans, alveolar macrophages isolated from patients
with acute lung injury express elevated amounts of PPAR-
γ and of PPAR-γ ligands such as prostaglandin D2 and 15-
HETE [12]. Indeed, the amount of 15-HETE found in these
patient’s bronchoalveolar lavage ﬂuid is more than 50 times
of that seen in lavage ﬂuid from healthy individuals. This
would be expected to reduce the extent of inﬂammation, and
hence may represent a step toward eventual resolution.
4.4. Otherlungdiseases
4.4.1. Endotoxicshock
Lipopolysaccharide from gram-negative bacteria can pro-
duce severe systemic inﬂammation and multiorgan failure,
including lung injury. The ability of PPAR-γ agonists to
block lipopolysaccharide-induced inﬂammatory changes in
macrophages in vitro has been well described. In an animal
model, Kaplan et al. showed that this observation may have
clinical relevance [125]. In this study, intraperitoneal injec-
tionoflipopolysaccharideinplacebo-treatedmiceresultedin
severe inﬂammatory changes in the lung, including hemor-
rhage, inﬁltration of neutrophils, and reduction of the alveo-
lar space, that were visible within 6 hours. Increased expres-
sions of intercellular adhesion molecule-1, vascular cellular
adhesion molecule-1, and E-selectin were associated with
activation of NF-κB and decreased expression of PPAR-γ;
seventy-two-hour mortality was 91%. Treatment with 15d-
PGJ2, beginning 3 hours after lipopolysaccharide injection
and continuing every 12 hours thereafter, downregulated ex-
pression of adhesion molecules, reduced neutrophil inﬁltra-
tion, and decreased mortality to 45%. Binding of NF-κBt o
DNA was decreased, while expression and DNA binding of
PPAR-γ was increased, as was expression of the protective
heat shock protein 70.
Liu et al. obtained results in rats similar to those seen by
Kaplan et al. in mice [126]. Speciﬁcally, rosiglitazone treat-
ment began 30 minutes before lipopolysaccharide injection
and in some cases the PPAR-γ antagonist GW9662 was ad-
ministered 20 minutes before rosiglitazone. In the absence
of rosiglitazone, lung edema and histological injury were ap-
parent within 4 hours. These were signiﬁcantly reduced by
rosiglitazone, which also produced a 71% reduction of the
increase in myeloperoxidase activity (a marker for the pres-
ence of neutrophils) and an 84% reduction of the increase in
malondialdehyde levels. This was accompanied by a marked
decrease in inducible NO synthase mRNA and protein. All
these rosiglitazone eﬀects were blocked by the PPAR-γ an-
tagonist GW9662.
Although these are animal studies and do not di-
rectly demonstrate involvement of either PPAR-γ or alveolarMonica R. Smith et al. 7
+
+
+
Inﬂammation
Phagocytosis
Apoptotic
neutrophils
IL-4
NADPH
oxidase
PPARγ
CD36
AM
PPARγ
AM
H2O2
TNF, IL-12
iNOS/NO
MMP Ligands
PPARγ
FcγR
Bacteria
Surfactant layer
AM
Surfactant
PPARγ
Monocyte
Fibroblast
Red
cells
Endothelial
cell
Interstitium
Type II cell
Epithelial
basement membrane
Type I cell
Diﬀerentiation
Alveolar air space
Figure 1: The alveolar macrophage: role in immunity and eﬀects of PPAR-γ.P P A R - γ promotes diﬀerentiation of monocytes into AMs, then
mediates eﬀects that suppress AMs’ proinﬂammatory activities while upregulating phagocytosis through both CD36 and Fcγ surface re-
ceptors. Interaction with foreign substances causes the AM to secrete a variety of inﬂammatory molecules such as TNF-α, IL-12, H2O2,
nitric oxide, and MMPs. This inﬂammatory response is suppressed, however, by the production of substances such as IL-4 that reinforce
PPAR-γ activity. Alveolar surfactant also contains lipids that can stimulate PPAR-γ, resulting in suppression of AM inﬂammatory activ-
ity. PPAR-γ activation also enhances AM phagocytosis of bacteria and apoptotic neutrophils present in the closing stages of inﬂammation.
Thus, inﬂammation becomes self-limiting. Abbreviations: AM = alveolar macrophage; FcγR = surface receptor recognizing the Fc portion
of immunoglobulin G; iNOS = inducible nitric oxide synthase; MMP = matrix metalloproteinase.
macrophages in the eﬀects observed, they suggest that early
treatment with PPAR-γ agonists could ameliorate the eﬀects
of endotoxemia, at least in the lung and probably elsewhere.
4.4.2. Asthma
The alveolar macrophage has been described as “the forgot-
ten cell in asthma” [127]. Asthma is an exaggerated response
of the lung’s adaptive immune system to speciﬁc inhaled
antigens—aresponsethatthealveolarmacrophagedownreg-
ulatesinmostcircumstances.Itisthusnotsurprisingthatde-
pletion of alveolar macrophages led to an enhanced response
to challenge with an antigen to which mice had previously
been sensitized [128]. As discussed by Peters-Golden, alve-
olar macrophages exert a variety of eﬀects that could lead
to suppression of exaggerated asthmatic responses [127]a n d
many of these are precisely the eﬀects that are elicited and
maintained by PPAR-γ.I m p o r t a n t l y ,a l l e r g e nc h a l l e n g ei n
asthmatic patients has been found to downregulate PPAR-
γ levels in alveolar macrophages [129]. Otherwise, how-
ever, the contribution of PPAR-γ to alveolar macrophage re-
sponses in asthma has not been explicitly investigated.
5. CONCLUSIONS
Amongthemanyoften-overlookedrolesofPPAR-γ isitscen-
tral position in regulating the lung’s response to pathogens
and other noxious elements drawn in with inspired air. The
lung must be ableto respond eﬀectively,yet tocontrolthein-
ﬂammatory response generated in response to foreign agents
within the alveolar space. The alveolar macrophage is pivotal
in this respect. The ability of these cells to engulf unwanted
particlesrepresentstheﬁrstlineofdefense,yetwhennotfully
activated (e.g., by interactions with its Toll-likereceptors)8 PPAR Research
serves to strongly dampen responses by the lung’s adap-
tive immune system. However, when these cells have been
suﬃciently activated by danger signals within the alveolus,
alveolar macrophages release molecules that attract and acti-
vate other elements of the innate and adaptive immune sys-
tems. Finally, the macrophage’s ability to scavenge apoptotic
neutrophils is essential for resolution of inﬂammation once
the need has passed.
The central role of PPAR-γ in regulating the activa-
tional state of alveolar macrophages is becoming increas-
ingly clear (see Figure 1). Many studies have now shown that
macrophage activation is inhibited by PPAR-γ and/or PPAR-
γ agonists. This is typically associated with decreases in NF-
κBactivity,withonelikelymechanismbeingunavailabilityof
that transcription factor’s obligate coactivators because they
are being used by PPAR-γ instead. Conversely, activation of
alveolar macrophages is associated with low levels of PPAR-γ
a n dh i g hl e v e l so fN F - κBa c t i v i t y .
Many aspects of alveolar macrophage function and the
role of PPAR-γ in regulating these functions remain un-
clear. Especially uncertain are how these responses con-
tribute to pathological conditions such as asthma and acute
lung injury. All of these aspects deserve further investiga-
tion, with special attention to the possibility that PPAR-
γ agonists may prove therapeutically useful in a variety
of lung diseases in which they have not previously been
considered.
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